Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1972 1
1980 1
1989 1
1991 1
1992 1
1993 1
2000 1
2001 1
2002 2
2004 4
2005 2
2006 2
2007 1
2008 5
2009 11
2010 3
2011 6
2012 5
2013 4
2014 3
2015 9
2016 10
2017 6
2018 6
2019 6
2020 5
2021 7
2022 7
2023 9
2024 10
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
Real-world analysis of teclistamab in 123 RRMM patients from Germany.
Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, Einsele H, Faltin J, Frenking J, Gezer D, Goldman-Mazur S, Hänel M, Hoegner M, Kortuem KM, Krönke J, Kull M, Leitner T, Mann C, Mecklenbrauck R, Merz M, Morgner A, Nogai A, Raab MS, Teipel R, Wäsch R, Rasche L. Riedhammer C, et al. Among authors: kull m. Leukemia. 2024 Feb;38(2):365-371. doi: 10.1038/s41375-024-02154-5. Epub 2024 Jan 20. Leukemia. 2024. PMID: 38245601 Free PMC article.
The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities.
Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, Sträng E, Kull M, Grünschläger F, Krüger J, Benary M, Müller S, Gao X, Murgai A, Haji M, Schmidt A, Lutz R, Nogai A, Braune J, Laue D, Langer C, Khandanpour C, Bassermann F, Döhner H, Engelhardt M, Straka C, Hundemer M, Beule D, Haas S, Keller U, Einsele H, Bullinger L, Knop S, Mertins P, Krönke J. Ramberger E, et al. Among authors: kull m. Nat Cancer. 2024 Aug;5(8):1267-1284. doi: 10.1038/s43018-024-00784-3. Epub 2024 Jun 28. Nat Cancer. 2024. PMID: 38942927 Free PMC article.
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma.
Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M, Braune J, Brioli A, Brunner F, Dampmann M, Fenk R, Gezer DN, Goldman-Mazur S, Hanoun C, Högner M, Khandanpour C, Kolditz K, Kos I, Krönke J, Kull M, Landrin V, Leitner T, Merz M, von Metzler I, Michel CS, Müller-Tidow C, Theurich S, Trautmann-Grill K, Wäsch R, Zukovs R, Hänel M, Rasche L, Raab MS. Frenking JH, et al. Among authors: kull m. Hemasphere. 2025 Apr 17;9(4):e70114. doi: 10.1002/hem3.70114. eCollection 2025 Apr. Hemasphere. 2025. PMID: 40248128 Free PMC article.
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma.
Grieb N, Oeser A, Ferle M, Hanke F, Flossdorf S, Sauer S, Goldschmidt H, Müller-Tidow C, Salwender HJ, Fenk R, Engelhardt M, Zeiser R, Vucinic V, Franke GN, Blau IW, Teschner D, Einsele H, Kimmich C, Kull M, Besemer B, Gagelmann N, Kröger N, Neumuth T, Platzbecker U, Merz M; German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST). Grieb N, et al. Among authors: kull m. Bone Marrow Transplant. 2025 Mar;60(3):335-345. doi: 10.1038/s41409-024-02490-1. Epub 2024 Dec 5. Bone Marrow Transplant. 2025. PMID: 39638882 Free PMC article.
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Hungria V, et al. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15. Lancet Haematol. 2025. PMID: 40680752 Clinical Trial.
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.
Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K, Kochs G, Schwemmle M, Lang-Meli J, Maas M, Roehlen N, Karl V, Graeser A, Sogukpinar O, von Metzler I, Grathwohl D, Rasche L, Hebart H, Kull M, Emmerich F, Waller CF, Duyster J, Engelhardt M, Hartmann TN, Bengsch B, Boettler T, Neumann-Haefelin C, Hofmann M, Thimme R, Luxenburger H. Shoumariyeh K, et al. Among authors: kull m. Vaccines (Basel). 2024 Nov 1;12(11):1249. doi: 10.3390/vaccines12111249. Vaccines (Basel). 2024. PMID: 39591152 Free PMC article.
118 results